NO20080371L - Fremgangsmate for a forutsi responsen overfor en behandling - Google Patents
Fremgangsmate for a forutsi responsen overfor en behandlingInfo
- Publication number
- NO20080371L NO20080371L NO20080371A NO20080371A NO20080371L NO 20080371 L NO20080371 L NO 20080371L NO 20080371 A NO20080371 A NO 20080371A NO 20080371 A NO20080371 A NO 20080371A NO 20080371 L NO20080371 L NO 20080371L
- Authority
- NO
- Norway
- Prior art keywords
- marker gene
- response
- growth factor
- treatment
- patient
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000003550 marker Substances 0.000 abstract 7
- 108090000623 proteins and genes Proteins 0.000 abstract 7
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 abstract 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 2
- 101800003838 Epidermal growth factor Proteins 0.000 abstract 2
- 239000004010 HER dimerization inhibitor Substances 0.000 abstract 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 abstract 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 abstract 2
- 229940116977 epidermal growth factor Drugs 0.000 abstract 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 2
- 102100038778 Amphiregulin Human genes 0.000 abstract 1
- 108010033760 Amphiregulin Proteins 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05017663 | 2005-08-12 | ||
| PCT/EP2006/004950 WO2007019899A2 (en) | 2005-08-12 | 2006-05-24 | Method for predicting the response to a treatment with a her dimerization inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20080371L true NO20080371L (no) | 2008-05-09 |
Family
ID=35511140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20080371A NO20080371L (no) | 2005-08-12 | 2008-01-21 | Fremgangsmate for a forutsi responsen overfor en behandling |
Country Status (32)
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| IL152656A0 (en) | 2000-05-19 | 2003-06-24 | Genentech Inc | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
| SV2006002143A (es) * | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
| AU2005287404B2 (en) | 2004-07-22 | 2009-05-07 | Genentech, Inc. | HER2 antibody composition |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| AU2005314127A1 (en) * | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a HER inhibitor |
| MX2007008768A (es) * | 2005-01-21 | 2007-10-19 | Genentech Inc | Dosificacion fija de anticuerpos her. |
| CN103251946A (zh) * | 2005-02-23 | 2013-08-21 | 健泰科生物技术公司 | 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活 |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| ATE520979T1 (de) * | 2005-08-24 | 2011-09-15 | Bristol Myers Squibb Co | Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors |
| PE20090681A1 (es) * | 2007-03-02 | 2009-06-10 | Genentech Inc | Prediccion de respuesta a un inhibidor her |
| JP5433189B2 (ja) * | 2007-09-28 | 2014-03-05 | 承一 尾崎 | Ｍｐｏ−ａｎｃａ関連血管炎の被験者に対する治療の効果を予測する材料を提供する方法 |
| US10416162B2 (en) * | 2007-12-20 | 2019-09-17 | Monogram Biosciences, Inc. | Her2 diagnostic methods |
| EP2237792B1 (en) * | 2007-12-26 | 2017-05-24 | Vaccinex, Inc. | Anti-c35 antibody combination therapies and methods |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| US9879267B2 (en) * | 2008-03-14 | 2018-01-30 | Genentech, Inc. | Genetic variations associated with drug resistance |
| AU2009246398A1 (en) * | 2008-05-14 | 2009-11-19 | Bristol-Myers Squibb Company | Predictors of patient response to treatment with EGF receptor inhibitors |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| WO2010065568A2 (en) | 2008-12-01 | 2010-06-10 | Laboratory Corporation Of America Holdings | METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95 |
| SG172983A1 (en) | 2009-01-15 | 2011-08-29 | Lab Corp America Holdings | Methods of determining patient response by measurement of her-3 |
| EP2387717B1 (en) * | 2009-01-15 | 2014-12-10 | Laboratory Corporation of America Holdings | Methods of determining patient response by measurement of her-2 expression |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| AU2011243958B2 (en) * | 2010-04-18 | 2015-01-22 | Yeda Research And Development Co. Ltd. | Molecules and methods of using same for treating ErbB/ErbB ligands associated diseases |
| US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
| US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
| US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
| AU2012204162B2 (en) * | 2011-01-07 | 2017-04-20 | Anji Pharmaceuticals Inc. | Chemosensory receptor ligand-based therapies |
| US9828635B2 (en) * | 2011-10-06 | 2017-11-28 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-ERBB3 antibodies |
| DK4403228T3 (da) | 2011-10-14 | 2025-10-13 | Hoffmann La Roche | Anvendelser for og fremstillet artikel indbefattende HER2-dimeriseringshæmmeren pertuzumab |
| KR102231554B1 (ko) | 2012-01-06 | 2021-03-23 | 앤지 파마 유에스 엘엘씨 | 대사 장애를 치료하는 조성물 및 방법 |
| KR102035879B1 (ko) | 2012-01-06 | 2019-10-23 | 엘셀릭스 테라퓨틱스 인코포레이티드 | 바이구아나이드 조성물 및 대사 장애를 치료하는 방법 |
| RU2737727C2 (ru) | 2013-04-16 | 2020-12-02 | Дженентек, Инк. | Варианты пертузумаба и их аналитическая характеристика |
| US20160175401A1 (en) * | 2013-07-31 | 2016-06-23 | Dana-Farber Cancer Institute Inc. | Compoitions and methods for modulating thermogenesis using pth-related and egf-related compounds |
| EP2876442A1 (en) * | 2013-11-22 | 2015-05-27 | Institut de Cancérologie de l'Ouest | Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer |
| RU2020120593A (ru) | 2014-04-25 | 2020-09-01 | Дженентек, Инк. | Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом |
| WO2017014810A1 (en) * | 2015-07-17 | 2017-01-26 | Czerniecki Brian J | Identification of immunogenic mhc class ii peptides for immune-based therapy |
| EP3791891A1 (en) | 2014-07-17 | 2021-03-17 | Brian J. Czerniecki | Identification of immunogenic mhc class ii peptides for immune-based therapy |
| ES2984592T3 (es) | 2015-05-30 | 2024-10-30 | Hoffmann La Roche | Procedimientos de tratamiento de cáncer de mama metastásico no tratado previamente positivo para HER2 |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| CN105403704A (zh) * | 2015-12-31 | 2016-03-16 | 苏州市博纳泰科生物技术有限公司 | Her-2的荧光免疫层析检测方法及试剂盒 |
| EP3534948A1 (en) | 2016-11-04 | 2019-09-11 | Genentech, Inc. | Treatment of her2-positive breast cancer |
| AU2017387909A1 (en) | 2016-12-28 | 2019-06-27 | Genentech, Inc. | Treatment of advanced HER2 expressing cancer |
| TW202508629A (zh) | 2017-01-17 | 2025-03-01 | 美商建南德克公司 | 皮下her2抗體調配物 |
| KR20230144110A (ko) | 2017-03-02 | 2023-10-13 | 제넨테크, 인크. | Her2-양성 유방암 어쥬번트 치료 |
| KR20190140952A (ko) | 2017-04-24 | 2019-12-20 | 제넨테크, 인크. | 막관통 및 인접막 도메인에서의 erbb2/her2 돌연변이 |
| MY199134A (en) * | 2018-05-25 | 2023-10-17 | Bioneer Corp | Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis related diseases and respiratory diseases, comprising same |
| JP2023532122A (ja) | 2020-06-29 | 2023-07-26 | ジェネンテック， インコーポレイテッド | ペルツズマブにトラスツズマブを加えた固定用量配合剤 |
| WO2024036234A1 (en) * | 2022-08-09 | 2024-02-15 | Heligenics Inc. | Method for evaluating clinical relevance of genetic variance |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US6759217B2 (en) * | 1996-03-26 | 2004-07-06 | Oncomedx, Inc. | Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer |
| JP2001504326A (ja) | 1996-10-18 | 2001-04-03 | ジェネンテック インコーポレーテッド | 抗ＥｒｂＢ２抗体 |
| GEP20104998B (en) | 1999-06-25 | 2010-06-10 | Genentech Inc | Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer |
| US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| EP2261368A1 (en) * | 2002-03-13 | 2010-12-15 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
| US20040248151A1 (en) | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
| GB0215509D0 (en) | 2002-07-04 | 2002-08-14 | Novartis Ag | Marker genes |
| EP2263691B1 (en) * | 2002-07-15 | 2012-08-29 | F.Hoffmann-La Roche Ag | Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4) |
| ES2246191T1 (es) * | 2002-12-11 | 2006-02-16 | Ventana Medical Systems, Inc. | Metodo para predecir la respuesta a la terapia dirigida a her2. |
| WO2004071572A2 (en) | 2003-02-06 | 2004-08-26 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
| WO2004087887A2 (en) | 2003-04-01 | 2004-10-14 | Monogram Biosciences, Inc. | Intracellular complexes as biomarkers |
| KR101126560B1 (ko) | 2003-05-30 | 2012-04-05 | 도꾜 다이가꾸 | 약제 반응 예측 방법 |
| US20060204966A1 (en) | 2003-08-01 | 2006-09-14 | Spector Neil L | Treatment of cancers expressing p95 erbb2 |
| WO2005047534A2 (en) | 2003-10-28 | 2005-05-26 | Bayer Healthcare Ag | Methods and compositions for the response prediction of malig-nant neoplasia to treatment |
| TWM256978U (en) * | 2004-04-02 | 2005-02-11 | Nventec Appliances Corp | Electronic device |
| AU2005314127A1 (en) * | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a HER inhibitor |
| RU2300111C2 (ru) * | 2005-06-15 | 2007-05-27 | Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) | Способ прогнозирования течения заболевания раком молочной железы |
-
2006
- 2006-05-19 US US11/438,033 patent/US7700299B2/en not_active Expired - Fee Related
- 2006-05-23 TW TW095118273A patent/TW200741010A/zh unknown
- 2006-05-24 PL PL06743052T patent/PL1915460T3/pl unknown
- 2006-05-24 JP JP2008525399A patent/JP2009504142A/ja active Pending
- 2006-05-24 AT AT10156100T patent/ATE539171T1/de active
- 2006-05-24 HR HR20110171T patent/HRP20110171T1/hr unknown
- 2006-05-24 KR KR1020087003440A patent/KR20080034922A/ko not_active Ceased
- 2006-05-24 WO PCT/EP2006/004950 patent/WO2007019899A2/en not_active Ceased
- 2006-05-24 EP EP06743052A patent/EP1915460B1/en active Active
- 2006-05-24 EP EP10156100A patent/EP2196547B1/en active Active
- 2006-05-24 DK DK06743052.0T patent/DK1915460T3/da active
- 2006-05-24 ES ES06743052T patent/ES2356066T3/es active Active
- 2006-05-24 KR KR1020117011685A patent/KR20110074921A/ko not_active Ceased
- 2006-05-24 AR ARP060102149A patent/AR057323A1/es not_active Application Discontinuation
- 2006-05-24 RU RU2008108907/10A patent/RU2408735C2/ru not_active IP Right Cessation
- 2006-05-24 PT PT06743052T patent/PT1915460E/pt unknown
- 2006-05-24 DE DE602006019265T patent/DE602006019265D1/de active Active
- 2006-05-24 BR BRPI0615001-2A patent/BRPI0615001A2/pt not_active IP Right Cessation
- 2006-05-24 RS RS20110132A patent/RS51859B/sr unknown
- 2006-05-24 MX MX2008001926A patent/MX2008001926A/es active IP Right Grant
- 2006-05-24 NZ NZ565270A patent/NZ565270A/en not_active IP Right Cessation
- 2006-05-24 UA UAA200803055A patent/UA93989C2/ru unknown
- 2006-05-24 CA CA002616913A patent/CA2616913A1/en not_active Abandoned
- 2006-05-24 SI SI200630946T patent/SI1915460T1/sl unknown
- 2006-05-24 AT AT06743052T patent/ATE493514T1/de active
- 2006-05-24 AU AU2006281746A patent/AU2006281746B2/en not_active Ceased
- 2006-05-24 CN CNA2006800289513A patent/CN101405405A/zh not_active Withdrawn
- 2006-05-24 CN CN200910204668A patent/CN101705287A/zh active Pending
-
2008
- 2008-01-21 IL IL188923A patent/IL188923A0/en unknown
- 2008-01-21 NO NO20080371A patent/NO20080371L/no not_active Application Discontinuation
- 2008-01-24 CR CR9686A patent/CR9686A/es not_active Application Discontinuation
- 2008-02-06 MA MA30621A patent/MA31549B1/fr unknown
- 2008-02-11 EC EC2008008171A patent/ECSP088171A/es unknown
-
2009
- 2009-11-24 US US12/624,443 patent/US20100112603A1/en not_active Abandoned
-
2010
- 2010-04-19 RU RU2010115252/10A patent/RU2010115252A/ru not_active Application Discontinuation
- 2010-07-06 CL CL2010000720A patent/CL2010000720A1/es unknown
-
2011
- 2011-03-15 CY CY20111100286T patent/CY1111612T1/el unknown
- 2011-04-11 ZA ZA2011/02688A patent/ZA201102688B/en unknown
- 2011-05-19 AU AU2011202339A patent/AU2011202339A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20080371L (no) | Fremgangsmate for a forutsi responsen overfor en behandling | |
| NO20074389L (no) | Bestemmelse av respondere til kjemoterapi | |
| NZ593225A (en) | Gene expression markers (CMYC and Ki-67) for colorectal cancer prognosis | |
| WO2008089994A8 (en) | Use of igfbp-7 in the assessment of heart failure | |
| EA201170933A1 (ru) | Анализ нуклеиновых кислот, полученных из единичных клеток | |
| NZ587750A (en) | Molecular diagnosis and classification of malignant melanoma | |
| ATE511656T1 (de) | Verfahren zur risikobewertung von herzeingriffen auf gdf-15-basis | |
| ATE539170T1 (de) | Abschätzung und verringerung des risikos von graft-versus-host-reaktion | |
| MX2019006565A (es) | Medio de cultivo para celulas madre epiteliales y organoides que comprenden las celulas madre. | |
| ATE427995T1 (de) | Verbesserte methode zur transformation von sojabohnen | |
| WO2008091814A3 (en) | Assessment of asthma and allergen-dependent gene expression | |
| EP2232319B8 (en) | Method and system for identifying biological specimen slides using unique slide fingerprints | |
| SG156625A1 (en) | Method for measuring resistance or sensitivity to docetaxel | |
| DE602004015626D1 (de) | Bei brustkrebs | |
| WO2010127417A3 (en) | Hepatocellular carcinoma | |
| DK1675961T3 (da) | Fremgangsmåde til identifikation og/eller validering af receptortyrosinkinaseinhibitorer | |
| ATE510029T1 (de) | Verfahren zur analyse von nukleinsäuren | |
| ATE414701T1 (de) | Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren | |
| ATE459883T1 (de) | Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose | |
| WO2008029290A3 (en) | Identification of cancer stem cells using genetic markers | |
| WO2009132928A3 (en) | Molecular markers for cancer prognosis | |
| WO2005069187A3 (en) | Methods and system for the identification and characterization of peptides and their functional relationships by use of measures of correlation | |
| DE602007004570D1 (de) | Verwendung von Nogo-C bei der Beurteilung von Herzversagen | |
| GB0617116D0 (en) | Method of diagnosis | |
| WO2007127002A3 (en) | Protein markers of responsiveness to type iii receptor tyrosine kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |